

Urmi Dhagat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5100812/publications.pdf>

Version: 2024-02-01

26
papers

802
citations

567144

15
h-index

552653

26
g-index

27
all docs

27
docs citations

27
times ranked

1257
citing authors

#	ARTICLE	IF	CITATIONS
1	The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. <i>Immunological Reviews</i> , 2012, 250, 277-302.	2.8	192
2	Signalling by the \hat{I}^2c family of cytokines. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 189-201.	3.2	80
3	The \hat{I}^2c receptor family – Structural insights and their functional implications. <i>Cytokine</i> , 2015, 74, 247-258.	1.4	65
4	Dual Mechanism of Interleukin-3 Receptor Blockade by an Anti-Cancer Antibody. <i>Cell Reports</i> , 2014, 8, 410-419.	2.9	46
5	Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling. <i>Structure</i> , 2016, 24, 1271-1281.	1.6	46
6	Structure-Guided Design, Synthesis, and Evaluation of Salicylic Acid-Based Inhibitors Targeting a Selectivity Pocket in the Active Site of Human 20 \hat{I}^{\pm} -Hydroxysteroid Dehydrogenase (AKR1C1). <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3259-3264.	2.9	39
7	CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common \hat{I}^2 chain of the IL-3, GM-CSF and IL-5 receptors. <i>MAbs</i> , 2016, 8, 436-453.	2.6	38
8	Inhibitors of human 20 \hat{I}^{\pm} -hydroxysteroid dehydrogenase (AKR1C1). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2011, 125, 105-111.	1.2	34
9	A Salicylic Acid-Based Analogue Discovered from Virtual Screening as a Potent Inhibitor of Human 20 \hat{I}^{\pm} -Hydroxysteroid Dehydrogenase. <i>Medicinal Chemistry</i> , 2007, 3, 546-550.	0.7	33
10	A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. <i>Nature Communications</i> , 2018, 9, 386.	5.8	28
11	Role of the \hat{I}^2 Common (\hat{I}^2c) Family of Cytokines in Health and Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028514.	2.3	28
12	Selectivity Determinants of Inhibitor Binding to Human 20 \hat{I}^{\pm} -Hydroxysteroid Dehydrogenase: Crystal Structure of the Enzyme in Ternary Complex with Coenzyme and the Potent Inhibitor 3,5-Dichlorosalicylic Acid. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4844-4848.	2.9	26
13	CaMKK2 is inactivated by cAMP-PKA signaling and 14-3-3 adaptor proteins. <i>Journal of Biological Chemistry</i> , 2020, 295, 16239-16250.	1.6	24
14	Structure-based optimization and biological evaluation of human 20 \hat{I}^{\pm} -hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5309-5317.	2.6	21
15	EPO does not promote interaction between the erythropoietin and beta-common receptors. <i>Scientific Reports</i> , 2018, 8, 12457.	1.6	21
16	Molecular determinants for the stereospecific reduction of 3-ketosteroids and reactivity towards all-trans-retinal of a short-chain dehydrogenase/reductase (DHRS4). <i>Archives of Biochemistry and Biophysics</i> , 2009, 481, 183-190.	1.4	17
17	Inhibition of 3(17) \hat{I}^{\pm} -hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3245-3254.	1.4	12
18	Probing the inhibitor selectivity pocket of human 20 \hat{I}^{\pm} -hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2564-2567.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2014, 70, 358-361.	0.4	8
20	Structure of 3(17) β -hydroxysteroid dehydrogenase (AKR1C21) holoenzyme from an orthorhombic crystal form: an insight into the bifunctionality of the enzyme. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2007, 63, 825-830.	0.7	7
21	Structure of rat aldose reductase-like protein AKR1B14 holoenzyme: Probing the role of His269 in coenzyme binding by site-directed mutagenesis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 801-804.	1.0	7
22	Activation of aldo-keto reductase family member 1B14 (AKR1B14) by bile acids: Activation mechanism and bile acid-binding site. <i>Biochimie</i> , 2011, 93, 1476-1486.	1.3	6
23	Factorizing the role of a critical leucine residue in the binding of substrate to human 20 β -hydroxysteroid dehydrogenase (AKR1C1): Molecular modeling and kinetic studies of the Leu308Val mutant enzyme. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5274-5276.	1.0	5
24	The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. <i>MAbs</i> , 2018, 10, 1-12.	2.6	5
25	Structure of the G225P/G226P mutant of mouse 3(17) β -hydroxysteroid dehydrogenase (AKR1C21) ternary complex: implications for the binding of inhibitor and substrate. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2009, 65, 257-265.	2.5	3
26	Studies on a Tyr residue critical for the binding of coenzyme and substrate in mouse 3(17) β -hydroxysteroid dehydrogenase (AKR1C21): structure of the Y224D mutant enzyme. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2010, 66, 198-204.	2.5	3